



## **Tymlos Prior Authorization Request**

## Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:		Date:
Pat	ient's ID:	Patient's Date of Birth:
Ph	vsician's Name:	
Specialty:		NPI#:
	vsician Office Telephone:	
le	quest Initiated For:	
•	What is the indication?  ☐ Postmenopausal osteoporosis ☐ Other	<u>.                                    </u>
	What is the ICD-10 code?	
	Does the patient have a history of fragility fracture	res? If Yes, skip to #7  Yes  No
	What is the patient's pre-treatment T-score?	Unknown
•	Does the patient have any indicators of higher fra If Yes, indicate higher fracture risk indicator and	acture risk?  Yes  No nd skip to #7:
•	Has the patient failed prior treatment with or is intolerant to previous osteoporosis therapy (i.e., oral bisphosphonates or injectable antiresorptive agents)? ☐ Yes ☐ No	
	How many months of cumulative parathyroid hor teriparatide [Forteo]) has the patient received in h	rmone analog therapy (e.g., abaloparatide [Tymlos <sup>TM</sup> ] or his/her lifetime? months
	test that this information is accurate and tru ormation is available for review if requested	ue, and that documentation supporting this by CVS Caremark or the benefit plan sponsor.

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tymlos SGM - 6/2017.

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.